It is estimated that over eight million companion animals are diagnosed with cancer in the United States each year, and over 47% of all dogs over the age of ten will die from cancer. This increasing problem is segmented by the fact that current treatments are expensive and could potentially lead to negative side effects.
VetiVax is a revolutionary veterinary cancer treatment that uses the patient’s tumor cells to create a personalized immunotherapy. Using a surgically excised portion of the tumor, our laboratory creates a multi-dose VetiVax treatment that is administered subcutaneously over three weeks.
Torigen Pharmaceuticals, Inc.
Torigen Pharmaceuticals, Inc. is focused on providing veterinary cancer care solutions for companion animals. Our novel, personalized immunotherapy that uses the animals’ existing tumor cells to fight cancer. When combined with an innovative bulking agent, MIM™ (matrix immune modulator), an overall reduction in tumor size and inhibition of metastasis has been observed throughout multiple peer-reviewed publications. This is the basis and foundation for Torigen’s personalized veterinary cancer treatment, VetiVax.